[{"id":"26646272-f3f1-4cb9-84dd-16ded62b0796","acronym":"","url":"https://clinicaltrials.gov/study/NCT01875601","created_at":"2021-01-29T07:04:49.340Z","updated_at":"2025-02-25T12:36:34.409Z","phase":"Phase 1","brief_title":"NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors","source_id_and_acronym":"NCT01875601","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 06/11/2013","start_date":" 06/11/2013","primary_txt":" Primary completion: 09/08/2015","primary_completion_date":" 09/08/2015","study_txt":" Completion: 09/08/2015","study_completion_date":" 09/08/2015","last_update_posted":"2025-02-24"},{"id":"af39ac7b-da69-42b7-b46c-b6f44a751583","acronym":"","url":"https://clinicaltrials.gov/study/NCT03388632","created_at":"2021-01-18T16:43:29.165Z","updated_at":"2024-07-02T16:34:26.496Z","phase":"Phase 1","brief_title":"Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers","source_id_and_acronym":"NCT03388632","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • rhIL-15"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/05/2018","start_date":" 02/05/2018","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-13"},{"id":"d4c2f1f7-7ab0-4565-bc0b-f59cf09aba7a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01572493","created_at":"2023-03-06T20:01:22.302Z","updated_at":"2024-07-02T16:35:54.091Z","phase":"Phase 1","brief_title":"Continuous Infusion of rhIL-15 for Adults With Advanced Cancer","source_id_and_acronym":"NCT01572493","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL6 • TNFA • IL15","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 04/04/2012","start_date":" 04/04/2012","primary_txt":" Primary completion: 06/20/2019","primary_completion_date":" 06/20/2019","study_txt":" Completion: 07/02/2019","study_completion_date":" 07/02/2019","last_update_posted":"2023-03-06"},{"id":"71343729-1bac-4081-80f8-a294b7151b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT04185220","created_at":"2021-01-18T20:24:07.273Z","updated_at":"2024-07-02T16:35:58.235Z","phase":"Phase 1","brief_title":"Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome","source_id_and_acronym":"NCT04185220","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFRSF8 • IL15","pipe":"","alterations":" ","tags":["TNFRSF8 • IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Poteligeo (mogamulizumab-kpkc) • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 02/26/2020","start_date":" 02/26/2020","primary_txt":" Primary completion: 11/06/2020","primary_completion_date":" 11/06/2020","study_txt":" Completion: 05/18/2022","study_completion_date":" 05/18/2022","last_update_posted":"2023-01-04"},{"id":"e4dfc3e3-609f-407a-81af-e186b7ede706","acronym":"","url":"https://clinicaltrials.gov/study/NCT03905135","created_at":"2021-01-18T19:13:31.837Z","updated_at":"2024-07-02T16:36:04.092Z","phase":"Phase 1","brief_title":"Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies","source_id_and_acronym":"NCT03905135","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFRSF8 • IL15 • IL5","pipe":" | ","alterations":" PD-L1 expression","tags":["TNFRSF8 • IL15 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 03/25/2021","primary_completion_date":" 03/25/2021","study_txt":" Completion: 05/17/2022","study_completion_date":" 05/17/2022","last_update_posted":"2022-09-13"},{"id":"a007902a-0a7f-41d6-85c9-d3d6c51f4f3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02689453","created_at":"2021-01-18T13:07:06.175Z","updated_at":"2024-07-02T16:36:11.245Z","phase":"Phase 1","brief_title":"Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)","source_id_and_acronym":"NCT02689453","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • TNFRSF8 • CCR4 • IL2RA • CD4 • NCAM1 • CCR7 • CD52 • FAS • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["CD8 • TNFRSF8 • CCR4 • IL2RA • CD4 • NCAM1 • CCR7 • CD52 • FAS • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/19/2017","start_date":" 01/19/2017","primary_txt":" Primary completion: 06/15/2021","primary_completion_date":" 06/15/2021","study_txt":" Completion: 06/15/2021","study_completion_date":" 06/15/2021","last_update_posted":"2022-04-29"},{"id":"ec2197c4-0016-4dba-b7ff-d215f60c5c5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01727076","created_at":"2021-01-18T07:32:38.065Z","updated_at":"2024-07-02T16:37:17.894Z","phase":"Phase 1","brief_title":"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer","source_id_and_acronym":"NCT01727076","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CTLA4 • LAMP1 • IL15","pipe":"","alterations":" ","tags":["CTLA4 • LAMP1 • IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 02/15/2013","start_date":" 02/15/2013","primary_txt":" Primary completion: 06/30/2016","primary_completion_date":" 06/30/2016","study_txt":" Completion: 06/30/2016","study_completion_date":" 06/30/2016","last_update_posted":"2017-09-15"}]